FDA Orange Book · active-ingredient family
Levothyroxine sodium
Levothyroxine sodium: 14 brands, 19 generics; first approved Aug 21, 2000; generic available.
Generic availableHas discontinued products
Generic status & protection
Generic available: 19 ANDA applications approved.
Earliest patent expiry
Brands (NDA)
14
Generics (ANDA)
19
Listed patents
16
Next patent expiry
Aug 06, 2031
in 4 yr 10 mo
Brand (NDA) products
Originator applications
- ERMEZARLDMYLANNDA 2158092022
Approved strengths under this FDA application. Strength Dosage form Route Status TE 150MCG/5ML SOLUTION ORAL Discontinued - - LEVOTHYROXINE SODIUMRLDRSHIKMANDA 2142532021
Approved strengths under this FDA application. Strength Dosage form Route Status TE 100MCG/ML SOLUTION INTRAVENOUS Rx - - STEVENS JNDA 2140472020
Approved strengths under this FDA application. Strength Dosage form Route Status TE 100MCG/5ML SOLUTION ORAL Rx - - LEVOTHYROXINE SODIUMRLDRSFRESENIUS KABI USANDA 21063220193 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 100MCG/5ML (20MCG/ML) SOLUTION INTRAVENOUS Rx - 200MCG/5ML (40MCG/ML) SOLUTION INTRAVENOUS Rx - 500MCG/5ML (100MCG/ML) SOLUTION INTRAVENOUS Rx - - TIROSINT-SOLRLDIBSANDA 206977201615 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 13MCG/ML SOLUTION ORAL Rx - 25MCG/ML SOLUTION ORAL Rx - 50MCG/ML SOLUTION ORAL Rx - 75MCG/ML SOLUTION ORAL Rx - 88MCG/ML SOLUTION ORAL Rx - 100MCG/ML SOLUTION ORAL Rx - 112MCG/ML SOLUTION ORAL Rx - 125MCG/ML SOLUTION ORAL Rx - 137MCG/ML SOLUTION ORAL Rx - 150MCG/ML SOLUTION ORAL Rx - 175MCG/ML SOLUTION ORAL Rx - 200MCG/ML SOLUTION ORAL Rx - 37.5MCG/ML SOLUTION ORAL Rx - 44MCG/ML SOLUTION ORAL Rx - 62.5MCG/ML SOLUTION ORAL Rx - - LEVOTHYROXINE SODIUMRLDRSFRESENIUS KABI USANDA 20223120113 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 100MCG/VIAL POWDER INTRAVENOUS Rx AP 200MCG/VIAL POWDER INTRAVENOUS Rx AP 500MCG/VIAL POWDER INTRAVENOUS Rx AP - TIROSINTRLDIBSANDA 021924200715 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.025MG CAPSULE ORAL Rx - 0.05MG CAPSULE ORAL Rx - 0.075MG CAPSULE ORAL Rx - 0.1MG CAPSULE ORAL Rx - 0.125MG CAPSULE ORAL Rx - 0.15MG CAPSULE ORAL Rx - 0.112MG CAPSULE ORAL Rx - 0.137MG CAPSULE ORAL Rx - 0.088MG CAPSULE ORAL Rx - 0.175MG CAPSULE ORAL Rx - 0.2MG CAPSULE ORAL Rx - 0.013MG CAPSULE ORAL Rx - 0.0375MG CAPSULE ORAL Rx - 0.044MG CAPSULE ORAL Rx - 0.0625MG CAPSULE ORAL Rx - - THYRO-TABSRLDALVOGENNDA 021116200212 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 - SYNTHROIDRLDABBVIENDA 021402200212 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2 - LEVOXYLRLDKING PHARMSNDA 021301200112 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB3 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB3 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB3 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB3 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB3 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB3 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB3 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB3 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB3 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB3 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB3 0.3MG TABLET ORAL Discontinued - - UNITHROIDRLDSTEVENS JNDA 021210200012 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 - GENUS LIFESCIENCESNDA 021137200312 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 - EMD SERONO INCNDA 021292200212 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.025MG TABLET ORAL Discontinued - 0.05MG TABLET ORAL Discontinued - 0.075MG TABLET ORAL Discontinued - 0.088MG TABLET ORAL Discontinued - 0.1MG TABLET ORAL Discontinued - 0.112MG TABLET ORAL Discontinued - 0.125MG TABLET ORAL Discontinued - 0.137MG TABLET ORAL Discontinued - 0.15MG TABLET ORAL Discontinued - 0.175MG TABLET ORAL Discontinued - 0.2MG TABLET ORAL Discontinued - 0.3MG TABLET ORAL Discontinued - - CEDIPROF INCNDA 021342200212 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3
Generic (ANDA) products (19)
Abbreviated applications
- LEVOTHYROXINE SODIUMALEMBICANDA 216370202612 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB2 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB2 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB2 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB2 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB2 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB2 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB2 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB2 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB2 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB2 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB2 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB2 - LEVOTHYROXINE SODIUMONESOURCE SPECIALTYANDA 21672920253 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 100MCG/VIAL POWDER INTRAVENOUS Rx AP 200MCG/VIAL POWDER INTRAVENOUS Rx AP 500MCG/VIAL POWDER INTRAVENOUS Rx AP - LEVOTHYROXINE SODIUMXIROMEDANDA 2174952024
Approved strengths under this FDA application. Strength Dosage form Route Status TE 100MCG/VIAL POWDER INTRAVENOUS Rx AP - LEVOTHYROXINE SODIUMAUROBINDO PHARMAANDA 21641420245 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.137MG TABLET ORAL Discontinued - 0.15MG TABLET ORAL Discontinued - 0.175MG TABLET ORAL Discontinued - 0.2MG TABLET ORAL Discontinued - 0.3MG TABLET ORAL Discontinued - - LEVOTHYROXINE SODIUMZYDUS PHARMSANDA 21706620233 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 100MCG/VIAL POWDER INTRAVENOUS Rx AP 200MCG/VIAL POWDER INTRAVENOUS Rx AP 500MCG/VIAL POWDER INTRAVENOUS Rx AP - LEVOTHYROXINE SODIUMASCENT PHARMS INCANDA 215259202312 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB4 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB4 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB4 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB4 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB4 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB4 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB4 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB4 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB4 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB4 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB4 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB4 - LEVOTHYROXINE SODIUMMACLEODS PHARMSANDA 211417202212 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 - LEVOTHYROXINE SODIUMWATSON LABS TEVAANDA 207588202212 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 - LEVOTHYROXINE SODIUMANI PHARMSANDA 21325620213 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.088MG CAPSULE ORAL Discontinued - 0.1MG CAPSULE ORAL Discontinued - 0.125MG CAPSULE ORAL Discontinued - - LEVOTHYROXINE SODIUMANI PHARMSANDA 21136920206 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.075MG CAPSULE ORAL Discontinued - 0.15MG CAPSULE ORAL Discontinued - 0.112MG CAPSULE ORAL Discontinued - 0.2MG CAPSULE ORAL Discontinued - 0.137MG CAPSULE ORAL Discontinued - 0.175MG CAPSULE ORAL Discontinued - - LEVOTHYROXINE SODIUMACCORD HLTHCAREANDA 212399202012 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 - LEVOTHYROXINE SODIUMDR REDDYSANDA 2088372020
Approved strengths under this FDA application. Strength Dosage form Route Status TE 100MCG/VIAL POWDER INTRAVENOUS Discontinued - - LEVOTHYROXINE SODIUMAMNEALANDA 210831201912 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.025MG TABLET ORAL Discontinued - 0.05MG TABLET ORAL Discontinued - 0.075MG TABLET ORAL Discontinued - 0.088MG TABLET ORAL Discontinued - 0.1MG TABLET ORAL Discontinued - 0.112MG TABLET ORAL Discontinued - 0.125MG TABLET ORAL Discontinued - 0.137MG TABLET ORAL Discontinued - 0.15MG TABLET ORAL Discontinued - 0.175MG TABLET ORAL Discontinued - 0.2MG TABLET ORAL Discontinued - 0.3MG TABLET ORAL Discontinued - - LEVOTHYROXINE SODIUMLUPINANDA 209713201912 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3 - LEVOTHYROXINE SODIUMMAIA PHARMS INCANDA 20874920183 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 100MCG/VIAL POWDER INTRAVENOUS Rx AP 200MCG/VIAL POWDER INTRAVENOUS Rx AP 500MCG/VIAL POWDER INTRAVENOUS Rx AP - LEVOTHYROXINE SODIUMPIRAMAL CRITICALANDA 20616320162 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 100MCG/VIAL POWDER INTRAVENOUS Discontinued - 500MCG/VIAL POWDER INTRAVENOUS Discontinued - - LEVOTHYROXINE SODIUMPH HEALTHANDA 2053662015
Approved strengths under this FDA application. Strength Dosage form Route Status TE 200MCG/VIAL POWDER INTRAVENOUS Discontinued - - LEVOTHYROXINE SODIUMMERCK KGAAANDA 076752200511 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.025MG TABLET ORAL Discontinued - 0.05MG TABLET ORAL Discontinued - 0.075MG TABLET ORAL Discontinued - 0.088MG TABLET ORAL Discontinued - 0.1MG TABLET ORAL Discontinued - 0.112MG TABLET ORAL Discontinued - 0.125MG TABLET ORAL Discontinued - 0.15MG TABLET ORAL Discontinued - 0.175MG TABLET ORAL Discontinued - 0.2MG TABLET ORAL Discontinued - 0.3MG TABLET ORAL Discontinued - - LEVOTHYROXINE SODIUMMYLANANDA 076187200212 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET ORAL Rx AB1,AB2,AB3,AB4
Patent & exclusivity timeline
Protection horizon
Patent expiryExclusivity endToday
Listed patents
Orange Book patent file
| Patent | Expires | In | Type |
|---|---|---|---|
| 9050307 | in 4 yr 10 mo | Product | |
| 9168239 | in 5 yr 11 mo | Product | |
| 9168238 | in 5 yr 11 mo | Product | |
| 9006289 | in 6 yr | Product | |
| 9345772 | in 8 yr 6 mo | Product | |
| 11154498 | in 9 yr 11 mo | Product | |
| 9782376 | in 10 yr 3 mo | Product | |
| 11135190 | in 10 yr 3 mo | Product | |
| 12636270 | in 10 yr 3 mo | Product | |
| 10398669 | in 10 yr 3 mo | Product | |
| 11096913 | in 10 yr 6 mo | Product | |
| 10537538 | in 10 yr 6 mo | Product | |
| 10406108 | in 11 yr 7 mo | Product | |
| 10231931 | in 11 yr 7 mo | Product | |
| 11241382 | in 13 yr 1 mo | U-3757 | |
| 12564565 | in 18 yr 2 mo | Product |
Approval history
FDA approval span
First approval
26 yr 7 mo ago
Most recent approval
5 mo ago
Approvals span 2000–2026 across 33 FDA applications.
Brand (NDA) 1442%
Generic (ANDA) 1958%
Levothyroxine sodium: frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
Assyro Intelligence
Ask anything about Levothyroxine sodium
Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.
Evaluating for a team? Book a demo